{
    "data": {
        "issuanceinfo": {
            "industrycode": "204005",
            "industry": "醫療保健",
            "ipoprice": {
                "ceiling": "5.060",
                "floor": "3.600"
            },
            "ipodate": {
                "start": "2010-09-15 00:00:00",
                "end": "2010-09-20 00:00:00"
            },
            "minimumcapital": "4088.80",
            "subscribed": "86.00",
            "marketcap": "122.19億",
            "H_marketcap": "--",
            "pe": "41.27",
            "codesrate": "20.00",
            "link": "https://staticpdf.iqdii.com/stockdata/notice/Prospectus/00867/LTN20100915044_C.pdf",
            "ipopricing": "5.060",
            "resultdate": "2010-09-27 00:00:00",
            "enddate": "2010-09-20 00:00:00",
            "listeddate": "2010-09-28 00:00:00",
            "issuenumber": "20000.00萬",
            "issuenumberhK": "8000.00萬",
            "issuenumberother": "12000.00萬",
            "grayprice": "--",
            "sponsors": "瑞士銀行香港分行",
            "raisemoney": "81340.00萬",
            "use": "1、約8.3%或67.5百萬港元，將用于通過聘請更多合資格及專業員工及擴大醫院覆蓋范圍和地域范圍；\n2、約12.5%或101.7百萬港元，將用于興建新培訓及會議中心以供進行醫生培訓、醫學會議及其他推廣活動以及員工培訓；\n3、約8.3%或67.5百萬港元，將用于更換、改善或升級信息管理系統的軟硬件；\n4、約33.3%或270.9百萬港元，將用于收購在中國推廣銷售藥品的獨家授權及尋求并購合適制藥公司的機會。\n5、在取得理想的CMS024臨床進展后，約16.8%或136.7百萬港元，將用于興建一個生產廠房以供制造公司自行生產的藥品。\n6、約10%或87.8百萬港元，將用于撥款向供應商采購進口藥品以滿足中國市場對我們的授權引進產品日益增加的需求；\n7、約10%或81.3百萬港元，將用作我們的營運資金及其他一般企業用途；",
            "shares": 800,
            "leadagent": "瑞士銀行香港分行",
            "bookrunners": "瑞士銀行香港分行",
            "coordinator": "瑞士銀行香港分行",
            "firstDayOpen": "5.85",
            "IsEiio": 0,
            "Interestdays": 7,
            "PENote": "按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。",
            "OverAllotment": "有",
            "StabilizingManager": "瑞士銀行香港分行",
            "code": "E00867",
            "name": "康哲藥業",
            "fullname": "康哲藥業控股有限公司"
        },
        "institutioninfo": {
            "principaloffice": "香港北角英皇道510號港運大廈21樓2106室",
            "registrars": "香港中央證券登記有限公司",
            "registrarstel": "(852) 2862 8628",
            "chairman": "林剛",
            "secretary": "吳三燕",
            "telephone": "(852) 2369 3889",
            "substantialshareholders": "林剛(44.46%),Mondrian Investment Partners Ltd.(5.15%)",
            "principalactivities": "營銷、推廣、銷售及制造醫藥產品。",
            "website": "http://www.cms.net.cn"
        },
        "managerinfo": [],
        "investorinfo": [],
        "TotalShareholdingPercentage": 0
    },
    "result": 1,
    "Version": "4.5.190802.46408",
    "ElapsedMilliseconds": 510
}